179 related articles for article (PubMed ID: 22461886)
21. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.
Xu LF; Sun HL; Chen YT; Ni JY; Chen D; Luo JH; Zhou JX; Hu RM; Tan QY
J Gastroenterol Hepatol; 2013 Mar; 28(3):456-63. PubMed ID: 23216261
[TBL] [Abstract][Full Text] [Related]
22. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Park C; Kim JH; Kim PH; Kim SY; Gwon DI; Chu HH; Park M; Hur J; Kim JY; Kim DJ
Korean J Radiol; 2021 Feb; 22(2):213-224. PubMed ID: 32901464
[TBL] [Abstract][Full Text] [Related]
23. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
Liu F; Meng Z; Shao G; Wang J; Wang Z; Yang J; Yip CS; He D
Mol Biol Rep; 2017 Feb; 44(1):149-158. PubMed ID: 27981445
[TBL] [Abstract][Full Text] [Related]
24. Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization.
Sánchez-Delgado J; Vergara M; Machlab S; Lira A; Gómez Zaragoza C; Criado E; Rosinach M; Batista L; Arau B; Roget M; Ortiz J; Garcia C; Sort P; Casas M; Dalmau B; Forné M; Falcó J; Miquel M
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1453-1460. PubMed ID: 30113926
[TBL] [Abstract][Full Text] [Related]
25. Type of Necrosis Influences Prognosis in Hepatocellular Carcinoma After the First Transarterial Chemoembolization.
Wu ZJ; Xie YF; Chang X; Zhang L; Wu HY; Liu JB; Zhang JX; Sun P
Med Sci Monit; 2021 May; 27():e929884. PubMed ID: 33967266
[TBL] [Abstract][Full Text] [Related]
26. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma.
Kim HY; Park JW; Joo J; Jung SJ; An S; Woo SM; Kim HB; Koh YH; Lee WJ; Kim CM
J Gastroenterol Hepatol; 2012 Jun; 27(6):1051-6. PubMed ID: 22098152
[TBL] [Abstract][Full Text] [Related]
27. Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma.
Zhao H; Zhai X; Chen Z; Wan X; Chen L; Shen F; Ling C
Oncotarget; 2017 Jul; 8(28):45234-45241. PubMed ID: 28423370
[TBL] [Abstract][Full Text] [Related]
28. Platelet-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization plus apatinib in the treatment of advanced hepatocellular carcinoma.
Chen L; Ke Z; Xiong F; Kan X; Ren Y; Cao Y; Sun T; Yan L; Zhou G; Zheng C
Anticancer Drugs; 2020 Oct; 31(9):966-972. PubMed ID: 31977568
[TBL] [Abstract][Full Text] [Related]
29. Lactate Dehydrogenase Prior to Transarterial Hepatic Chemoperfusion Predicts Survival and Time to Progression in Patients with Uveal Melanoma Liver Metastases.
Ludwig J; Haubold J; Heusner TA; Bauer S; Siveke JT; Richly H; Wetter A; Umutlu L; Theysohn JM
Rofo; 2021 Jun; 193(6):683-691. PubMed ID: 33348383
[TBL] [Abstract][Full Text] [Related]
30. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
[TBL] [Abstract][Full Text] [Related]
31. A high value of serum des-γ-carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment.
Saito M; Seo Y; Yano Y; Miki A; Yoshida M; Azuma T
J Gastroenterol; 2012 Oct; 47(10):1134-42. PubMed ID: 22441533
[TBL] [Abstract][Full Text] [Related]
32. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
33. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
Li L; Gou CY; Li JY; Achakzai R; Li XH
Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
[TBL] [Abstract][Full Text] [Related]
34. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study.
Chen J; Lai L; Lin Q; Huang W; Cai M; Zhu K; Huang M
Oncotarget; 2017 Jan; 8(1):408-417. PubMed ID: 27880724
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas.
Zheng L; Li HL; Guo CY; Luo SX
Korean J Radiol; 2018; 19(2):237-246. PubMed ID: 29520181
[TBL] [Abstract][Full Text] [Related]
36. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
37. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
[TBL] [Abstract][Full Text] [Related]
38. Serum insulin-like growth factor-1 predicts disease progression and survival in patients with hepatocellular carcinoma who undergo transarterial chemoembolization.
Cho E; Kim HC; Lee JH; Jeong-Ju Yoo ; Choi WM; Cho YY; Lee MJ; Cho Y; Lee DH; Lee YB; Yu SJ; Kim YJ; Yoon JH; Chung JW; Kim CY; Lee HS
PLoS One; 2014; 9(3):e90862. PubMed ID: 24595361
[TBL] [Abstract][Full Text] [Related]
39. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
40. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy.
Kohles N; Nagel D; Jüngst D; Durner J; Stieber P; Holdenrieder S
Tumour Biol; 2012 Feb; 33(1):33-40. PubMed ID: 21931992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
